Recombinant anti-interleukin-9 antibodies

Details Recombinant anti-interleukin-9 antibodies Recombinant anti-interleukin-9 antibodies

2008-05-13

2008-05-13

Chan, Christina (Department: 1644)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Monoclonal antibody or fragment thereof

C530S388230, C424S133100

Reexamination Certificate

active

07371383

ABSTRACT:
The application describes neutralizing chimeric and humanized anti-human IL-9 antibodies, and the use thereof to identify neutralizing epitopes on human IL-9 and as medicaments to prevent and treat asthma, bronchial hyperresponsiveness, atopic allergy, and other related disorders. Particularly disclosed are recombinant antibodies derived from three murine anti-human IL-9 antibodies identified infra as MH9A3, MH9D1, and MH9L1.

REFERENCES:
patent: 4474893 (1984-10-01), Reading
patent: 4658019 (1987-04-01), Kung et al.
patent: 4714681 (1987-12-01), Reading
patent: 4925648 (1990-05-01), Hansen et al.
patent: 5017691 (1991-05-01), Lee et al.
patent: 5136021 (1992-08-01), Dembinski et al.
patent: 5147638 (1992-09-01), Esmon et al.
patent: 5149780 (1992-09-01), Plow et al.
patent: 5157112 (1992-10-01), Van Snick et al.
patent: 5196511 (1993-03-01), Plow et al.
patent: 5204445 (1993-04-01), Plow et al.
patent: 5208218 (1993-05-01), Van Snick et al.
patent: 5223395 (1993-06-01), Gero
patent: 5231024 (1993-07-01), Moeller et al.
patent: 5262520 (1993-11-01), Plow et al.
patent: 5306620 (1994-04-01), Ginsberg et al.
patent: 5334380 (1994-08-01), Kilbourn et al.
patent: 5360716 (1994-11-01), Ohmoto et al.
patent: 5426181 (1995-06-01), Lee et al.
patent: 5436154 (1995-07-01), Barbanti et al.
patent: 5478725 (1995-12-01), Lessey
patent: 5498694 (1996-03-01), Ruoslahti
patent: 5523209 (1996-06-01), Ginsberg et al.
patent: 5573920 (1996-11-01), Randle
patent: 5578704 (1996-11-01), Kim et al.
patent: 5589570 (1996-12-01), Tamura et al.
patent: 5601819 (1997-02-01), Wong et al.
patent: 5610279 (1997-03-01), Brockhaus et al.
patent: 5644034 (1997-07-01), Rathjen et al.
patent: 5652109 (1997-07-01), Kim et al.
patent: 5652110 (1997-07-01), Kim et al.
patent: 5656272 (1997-08-01), Le et al.
patent: 5658746 (1997-08-01), Coan et al.
patent: 5693612 (1997-12-01), Jonczyk et al.
patent: 5698195 (1997-12-01), Le et al.
patent: 5705481 (1998-01-01), Jonczyk et al.
patent: 5736138 (1998-04-01), Pfizenmaier et al.
patent: 5741488 (1998-04-01), Feldman et al.
patent: 5753230 (1998-05-01), Brooks et al.
patent: 5767071 (1998-06-01), Palladino et al.
patent: 5770565 (1998-06-01), Cheng et al.
patent: 5780426 (1998-07-01), Palladino et al.
patent: 5808029 (1998-09-01), Brockhaus et al.
patent: 5817457 (1998-10-01), Bird et al.
patent: 5824307 (1998-10-01), Johnson
patent: 5830678 (1998-11-01), Carter
patent: 5849692 (1998-12-01), Jonczyk et al.
patent: 5919452 (1999-07-01), Le et al.
patent: 5955572 (1999-09-01), Ruoslahti et al.
patent: 5958412 (1999-09-01), Welt et al.
patent: 5959087 (1999-09-01), Rathjen et al.
patent: 5968741 (1999-10-01), Plevy et al.
patent: 5985278 (1999-11-01), Mitjans et al.
patent: 5994510 (1999-11-01), Adair et al.
patent: 6036978 (2000-03-01), Gombotz et al.
patent: 6048861 (2000-04-01), Askew et al.
patent: 6090944 (2000-07-01), Hutchinson
patent: 6096707 (2000-08-01), Heino et al.
patent: 6114517 (2000-09-01), Monia et al.
patent: 6130231 (2000-10-01), Wityak et al.
patent: 6153628 (2000-11-01), Jin et al.
patent: 6160099 (2000-12-01), Jonak et al.
patent: 6162432 (2000-12-01), Wallner et al.
patent: 6171588 (2001-01-01), Carron et al.
patent: 6171787 (2001-01-01), Wiley
patent: 6261559 (2001-07-01), Levitt et al.
patent: 555 880 (1993-08-01), None
patent: WO 92/05793 (1992-04-01), None
patent: WO 96/40210 (1996-12-01), None
patent: WO 96/40210 (1996-12-01), None
patent: WO 98/08545 (1998-03-01), None
Rudikoff et al., Single amino acid substitution altering antigen-binding specificity, 1982, Proc. Natl. Acad. Sci. USA, 79:1979-1983.
Janeway et al., Immunobiology, 6th Ed., Garland Science, 2004, p. 110-112.
MacCallum et al. J. Mol. Biol. (1996) 262, 732-745.
Casset et al. (2003) BRC 307, 198-205.
Vajdos et al. J. Mol. Biol. (2002) 320, 415-428.
Holm et al, Molecular Biology,2007, vol. 44, 1075-1084.
Ashkenazi et al., 1991, “Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin,” Proc. Natl. Acad. Sci. USA 88(23):10535-10539.
Bani et al., 2002, “Inhibitory effects of relaxin on human basophils activated by stimulation of the Fc epsilon receptor, The role of nitric oxide,” Int. Immunopharmacol. 2(8):1195-1204.
Beeler et al., 1989, “Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function,” J. Virol. 63(7):2941-2950.
Busse et al., 2001, “Anti-immunoglobulin E for the treatment of allergic disease,” Curr. Opin. Allergy Clin. Immunol. 1(1):105-108.
Cao et al., 1996, “Kringle domains of human angiostatin. Characterization of the anti-proliferative activity on endothelial cells,” J. Biol. Chem. 271(46):29461-29467.
Carrell, 1999, “How serpins are shaping up,” Science 285(5435):1861.
Corren et al., 2003, “Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma,” J. Allergy Clin. Immunol. 111(1):87-90.
Crowley et al., 1993, “Prevention of metastasis by inhibition of the urokinase receptor,” Proc. Natl. Acad. Sci. USA 90(11):5021-5025.
Durie et al., 1994, “The role of CD40 in the regulation of humoral and cell-mediated immunity,” Immunol. Today 15(9):406-411.
Finn et al., 2003, “Omalizumab improves asthma-related quality of life in patients with severe allergic asthma,” J. Allergy Clin. Immunol. 111(2):278-284.
Finotto et al., 1997, “Glucocorticoids decrease tissue mast cell l number by reducing the production of the c-kit ligand, stem cell factor, by resident cells: in vitro and in vivo evidence in murine systems,” J. Clin. Invest. 99(7):1721-1728.
GenBank Accession No. AAC17735, May 29, 1998.
GenBank Accession No. A60480, Jul. 16, 1999.
GenBank Accession No. NM—176786, Aug. 23, 2004.
GenBank Accession No. NM—002186, Aug. 23, 2004.
GenBank Accession No. NM—000590, Oct. 26, 2004.
GenBank Accession No. NM—000206, Oct. 26, 2004.
GenBank Accession No. NP—789743, Aug. 23, 2004.
GenBank Accession No. NP—002177, Aug. 23, 2004.
GenBank Accession No. NP—000584, Oct. 28, 2004.
GenBank Accession No. NP—000197, Oct. 26, 2004.
Goodson et al., 1994, “High-affinity urokinase receptor antagonists identified with bacteriophage peptide display,” Proc. Natl. Acad. Sci. USA 91(15):7129-7133.
He et al., 2003, “The inhibition of mast cell activation by neutrophil lactoferrin: uptake by mast cells and interaction with tryptase, chymase and cathepsin G,” Biochem. Pharmacol. 65(6):1007-1015.
Heinrich et al., 2000, “Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor,” Blood 96(3):925-932.
Ito et al., 1999, “FK506 and clycosporin A inhibit stem cell factor-dependent cell proliferation/survival, while inducing upregulation of c-kit expression in cells of the mast cell line MC/9,” Arch. Dermatol. Res. 291(5):275-283.
Johnson et al., 1997, “Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus,” J. Infect. Dis. 176(5):1215-24.
Kohno et al., 1990, “A second tumor necrosis factor receptor gene product can shed a naturally occuring tumor necrosis factor inhibitor,” Proc. Natl. Acad. Sci. USA 87(21):8331-8335.
Kostelny et al., 1992, J. Immunol. 148:1547-1553.
Leung et al., 2003, “Effect of anti-IgE therapy in patients with peanut allergy,” N. Engl. J. Med. 348(11):986-993.
Mendiaz et al., 1996, “Epitope mapping and immunoneutralization of recombinant human stem-cell factor,” Eur. J. Biochem. 239(3):842-849.
Metcalfe et al., 1995, “Mast cell ontogeny and apoptosis,” Exp. Dermatol. 4(4 Pt 2):227-230.
Min et al., 1996, “Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice,” Cancer Res. 56(10):2428-2433.
Miyajima et al.

Affiliated with

Also associated with

Rating

Recombinant anti-interleukin-9 antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Recombinant anti-interleukin-9 antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant anti-interleukin-9 antibodies will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2790722